Affordable Access

Access to the full text

Endoscopic vacuum therapy versus stent treatment of esophageal anastomotic leaks (ESOLEAK): study protocol for a prospective randomized phase 2 trial

  • Tachezy, Michael1
  • Chon, Seung-Hun2
  • Rieck, Isabel3
  • Kantowski, Marcus1
  • Christ, Hildegard4
  • Karstens, Karl1
  • Gebauer, Florian2
  • Goeser, Tobias3
  • Rösch, Thomas1
  • Izbicki, Jakob R.1
  • Bruns, Christiane J.2
  • 1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany , Hamburg (Germany)
  • 2 University Hospital Cologne, Kerpener Str. 62, Cologne, 50937, Germany , Cologne (Germany)
  • 3 University Hospital Cologne, Cologne, Germany , Cologne (Germany)
  • 4 University of Cologne, Cologne, Germany , Cologne (Germany)
Published Article
Springer (Biomed Central Ltd.)
Publication Date
Jun 02, 2021
DOI: 10.1186/s13063-021-05315-4
Springer Nature


BackgroundIntrathoracic anastomotic leaks represent a major complication after Ivor Lewis esophagectomy. There are two promising endoscopic treatment strategies in the case of leaks: the placement of self-expanding metal stents (SEMS) or endoscopic vacuum therapy (EVT). Up to date, there is no prospective data concerning the optimal endoscopic treatment strategy. This is a protocol description for the ESOLEAK trial, which is a first small phase 2 randomized trial evaluating the quality of life after treatment of anastomotic leaks by either SEMS placement or EVT.MethodsThis phase 2 randomized trial will be conducted at two German tertiary medical centers and include a total of 40 patients within 2 years. Adult patients with histologically confirmed esophageal cancer, who have undergone Ivor Lewis esophagectomy and show an esophagogastric anastomotic leak on endoscopy or present with typical clinical signs linked to an anastomotic leak, will be included in our study taking into consideration the exclusion criteria. After endoscopic verification of the anastomotic leak, patients will be randomized in a 1:1 ratio into two treatment groups. The intervention group will receive EVT whereas the control group will be treated with SEMS. The primary endpoint of this study is the subjective quality of life assessed by the patient using a systematic and validated questionnaire (EORTC QLQ C30, EORTC QLQ-OES18 questionnaire). Important secondary endpoints are healing rate, period of hospitalization, treatment-related complications, and overall mortality.DiscussionThe latest meta-analysis comparing implantation of SEMS with EVT in the treatment of esophageal anastomotic leaks suggested a higher success rate for EVT. The ESOLEAK trial is the first study comparing both treatments in a prospective manner. The aim of the trial is to find suitable endpoints for the treatment of anastomotic leaks as well as to enable an adequate sample size calculation and evaluate the feasibility of future interventional trials. Due to the exploratory design of this pilot study, the sample size is too small to answer the question, whether EVT or SEMS implantation represents the superior treatment strategy.Trial NCT03962244. Registered on May 23, 2019.DRKS-ID DRKS00007941

Report this publication


Seen <100 times